# Intellia Therapeutics, Inc.: financial statements, quarterly

NTLA · Nasdaq · CIK 1652130 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ntla.md) · [Financials](/companies/ntla/financials.md) · [Filings](/companies/ntla/filings.md) · [Insiders](/companies/ntla/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ntla/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.0](/filings/0000950170-24-123276.md) | [(1.9) d](/filings/0001193125-26-076550.md) | [28.9](/filings/0000950170-25-066914.md) | [7.0](/filings/0000950170-25-104987.md) | [9.1](/filings/0001193125-25-269680.md) | [12.9 d](/filings/0001193125-26-076550.md) | [16.6](/filings/0001193125-26-215740.md) | [14.2](/filings/0001193125-26-337952.md) | [13.8](/filings/0001193125-25-269680.md) | [23.0 d](/filings/0001193125-26-076550.md) | [15.0](/filings/0001193125-26-215740.md) | [7.7](/filings/0001193125-26-337952.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [114](/filings/0000950170-24-123276.md) | [109 d](/filings/0001193125-26-076550.md) | [112](/filings/0000950170-25-066914.md) | [114](/filings/0000950170-25-104987.md) | [123](/filings/0001193125-25-269680.md) | [117 d](/filings/0001193125-26-076550.md) | [108](/filings/0001193125-26-215740.md) | [97.0](/filings/0001193125-26-337952.md) | [94.7](/filings/0001193125-25-269680.md) | [88.7 d](/filings/0001193125-26-076550.md) | [80.7](/filings/0001193125-26-215740.md) | [82.6](/filings/0001193125-26-337952.md) |
| Operating income | $m | [(131)](/filings/0000950170-24-123276.md) | [(140) d](/filings/0001193125-26-076550.md) | [(114)](/filings/0000950170-25-066914.md) | [(139)](/filings/0000950170-25-104987.md) | [(145)](/filings/0001193125-25-269680.md) | [(136) d](/filings/0001193125-26-076550.md) | [(121)](/filings/0001193125-26-215740.md) | [(110)](/filings/0001193125-26-337952.md) | [(111)](/filings/0001193125-25-269680.md) | [(98.7) d](/filings/0001193125-26-076550.md) | [(101)](/filings/0001193125-26-215740.md) | [(113)](/filings/0001193125-26-337952.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(122)](/filings/0000950170-24-123276.md) | [(132) d](/filings/0001193125-26-076550.md) | [(107)](/filings/0001193125-25-269680.md) | [(147)](/filings/0001193125-25-269680.md) | [(136)](/filings/0001193125-25-269680.md) | [(129) d](/filings/0001193125-26-076550.md) | [(114)](/filings/0001193125-26-337952.md) | [(101)](/filings/0001193125-26-337952.md) | [(101)](/filings/0001193125-25-269680.md) | [(95.8) d](/filings/0001193125-26-076550.md) | [(96.2)](/filings/0001193125-26-337952.md) | [(107)](/filings/0001193125-26-337952.md) |
| Diluted EPS | $ per share | [(1.38)](/filings/0000950170-24-123276.md) | not reported | [(1.12)](/filings/0000950170-25-066914.md) | [(1.52)](/filings/0000950170-25-104987.md) | [(1.34)](/filings/0001193125-25-269680.md) | not reported | [(1.10)](/filings/0001193125-26-215740.md) | [(0.98)](/filings/0001193125-26-337952.md) | [(0.92)](/filings/0001193125-25-269680.md) | not reported | [(0.81)](/filings/0001193125-26-215740.md) | [(0.80)](/filings/0001193125-26-337952.md) |
| Basic EPS | $ per share | [(1.38)](/filings/0000950170-24-123276.md) | not reported | [(1.12)](/filings/0000950170-25-066914.md) | [(1.52)](/filings/0000950170-25-104987.md) | [(1.34)](/filings/0001193125-25-269680.md) | not reported | [(1.10)](/filings/0001193125-26-215740.md) | [(0.98)](/filings/0001193125-26-337952.md) | [(0.92)](/filings/0001193125-25-269680.md) | not reported | [(0.81)](/filings/0001193125-26-215740.md) | [(0.80)](/filings/0001193125-26-337952.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [168](/filings/0000950170-24-123276.md) | [227](/filings/0001193125-26-076550.md) | [172](/filings/0000950170-25-066914.md) | [131](/filings/0000950170-25-104987.md) | [120](/filings/0001193125-25-269680.md) | [189](/filings/0001193125-26-076550.md) | [127](/filings/0001193125-26-215740.md) | [156](/filings/0001193125-26-337952.md) | [193](/filings/0001193125-25-269680.md) | [155](/filings/0001193125-26-337952.md) | [135](/filings/0001193125-26-215740.md) | [106](/filings/0001193125-26-337952.md) |
| Current assets | $m | [893](/filings/0000950170-23-062011.md) | [998](/filings/0000950170-25-029007.md) | [884](/filings/0000950170-24-057046.md) | [757](/filings/0000950170-24-093907.md) | [711](/filings/0000950170-24-123276.md) | [640](/filings/0001193125-26-076550.md) | [551](/filings/0000950170-25-066914.md) | [496](/filings/0000950170-25-104987.md) | [582](/filings/0001193125-25-269680.md) | [528](/filings/0001193125-26-337952.md) | [466](/filings/0001193125-26-215740.md) | [528](/filings/0001193125-26-337952.md) |
| Total assets | $m | [1,243](/filings/0000950170-23-062011.md) | [1,301](/filings/0000950170-25-029007.md) | [1,260](/filings/0000950170-24-057046.md) | [1,192](/filings/0000950170-24-093907.md) | [1,173](/filings/0000950170-24-123276.md) | [1,191](/filings/0001193125-26-076550.md) | [986](/filings/0000950170-25-066914.md) | [899](/filings/0000950170-25-104987.md) | [925](/filings/0001193125-25-269680.md) | [842](/filings/0001193125-26-337952.md) | [759](/filings/0001193125-26-215740.md) | [857](/filings/0001193125-26-337952.md) |
| Current liabilities | $m | [92.0](/filings/0000950170-23-062011.md) | [115](/filings/0000950170-25-029007.md) | [97.9](/filings/0000950170-24-057046.md) | [105](/filings/0000950170-24-093907.md) | [106](/filings/0000950170-24-123276.md) | [111](/filings/0001193125-26-076550.md) | [113](/filings/0000950170-25-066914.md) | [95.5](/filings/0000950170-25-104987.md) | [93.7](/filings/0001193125-25-269680.md) | [104](/filings/0001193125-26-337952.md) | [76.4](/filings/0001193125-26-215740.md) | [79.4](/filings/0001193125-26-337952.md) |
| Total liabilities | $m | [206](/filings/0000950170-23-062011.md) | [251](/filings/0000950170-25-029007.md) | [223](/filings/0000950170-24-057046.md) | [220](/filings/0000950170-24-093907.md) | [211](/filings/0000950170-24-123276.md) | [319](/filings/0001193125-26-076550.md) | [206](/filings/0000950170-25-066914.md) | [184](/filings/0000950170-25-104987.md) | [177](/filings/0001193125-25-269680.md) | [171](/filings/0001193125-26-337952.md) | [138](/filings/0001193125-26-215740.md) | [129](/filings/0001193125-26-337952.md) |
| Shareholders' equity | $m | [1,037](/filings/0000950170-24-123276.md) | [1,050](/filings/0001193125-26-076550.md) | [1,036](/filings/0001193125-25-269680.md) | [971](/filings/0001193125-25-269680.md) | [963](/filings/0001193125-25-269680.md) | [872](/filings/0001193125-26-337952.md) | [780](/filings/0001193125-26-337952.md) | [(715)](/filings/0001193125-26-337952.md) | [748](/filings/0001193125-25-269680.md) | [671](/filings/0001193125-26-337952.md) | [621](/filings/0001193125-26-337952.md) | [728](/filings/0001193125-26-337952.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(101) d](/filings/0000950170-24-123276.md) | [(93.1) d](/filings/0001193125-26-076550.md) | [(121)](/filings/0000950170-25-066914.md) | [(58.2) d](/filings/0000950170-25-104987.md) | [(84.8) d](/filings/0001193125-25-269680.md) | [(85.2) d](/filings/0001193125-26-076550.md) | [(149)](/filings/0001193125-26-215740.md) | [(99.6) d](/filings/0001193125-26-337952.md) | [(76.9) d](/filings/0001193125-25-269680.md) | [(69.3) d](/filings/0001193125-26-076550.md) | [(117)](/filings/0001193125-26-215740.md) | [(83.1) d](/filings/0001193125-26-337952.md) |
| Capital expenditure | $m | [4.3 d](/filings/0000950170-24-123276.md) | [1.5 d](/filings/0001193125-26-076550.md) | [2.5](/filings/0000950170-25-066914.md) | [1.0 d](/filings/0000950170-25-104987.md) | [1.3 d](/filings/0001193125-25-269680.md) | [1.0 d](/filings/0001193125-26-076550.md) | [0.7](/filings/0001193125-26-215740.md) | [0.2 d](/filings/0001193125-26-337952.md) | [0.0 d](/filings/0001193125-25-269680.md) | [0.1 d](/filings/0001193125-26-076550.md) | [0.1](/filings/0001193125-26-215740.md) | [1.8 d](/filings/0001193125-26-337952.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [76.0](/filings/0000950170-23-062011.md) | [87.8](/filings/0000950170-24-057046.md) | [88.2](/filings/0000950170-24-093907.md) | [88.6](/filings/0000950170-24-123276.md) | [95.5](/filings/0000950170-25-066914.md) | [97.0](/filings/0000950170-25-104987.md) | [101](/filings/0001193125-25-269680.md) | [104](/filings/0001193125-26-215740.md) | [104](/filings/0001193125-26-337952.md) | [110](/filings/0001193125-25-269680.md) | [118](/filings/0001193125-26-215740.md) | [133](/filings/0001193125-26-337952.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 140,126,693 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337952.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.